Intrommune Therapeutics Supports Outcome of FDA Allergenic Product Advisory Committee Vote
16 sept. 2019 14h25 HE
|
Intrommune Therapeutics
New York, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly immunotherapy platform for the treatment of peanut and...